Neutralizing VEGF bioactivity with a soluble chimeric VEGF-receptor protein flt(1-3)IgG inhibits testosterone-stimulated prostate growth in castrated mice
- PMID: 14673953
- DOI: 10.1002/pros.10312
Neutralizing VEGF bioactivity with a soluble chimeric VEGF-receptor protein flt(1-3)IgG inhibits testosterone-stimulated prostate growth in castrated mice
Abstract
Background: Recent studies show that testosterone-stimulated growth of the glandular tissue in the ventral prostate in adult castrated rats is preceded by increased epithelial VEGF synthesis, endothelial cell proliferation, vascular growth, and increased blood flow. These observations suggest that testosterone-stimulated prostate growth could be angiogenesis dependent, and that VEGF could play a central role in this process.
Methods: Adult male mice were castrated and after 1 week treated with testosterone and vehicle, or with testosterone and a soluble chimeric VEGF-receptor flt(1-3)IgG protein.
Results: Treatment with testosterone markedly increased endothelial cell proliferation, vascular volume, and organ weight in the ventral prostate lobe in the vehicle groups, but these responses were inhibited but not fully prevented by anti-VEGF treatment. The testosterone-stimulated increase in epithelial cell proliferation was unaffected by flt(1-3)IgG, but endothelial and epithelial cell apoptosis were increased in the anti-VEGF compared to the vehicle-treated groups.
Conclusions: This study suggests that testosterone stimulates vascular growth in the ventral prostate lobe indirectly by increasing epithelial VEGF synthesis and that this is a necessary component in testosterone-stimulated prostate growth.
Copyright 2003 Wiley-Liss, Inc.
Similar articles
-
Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats.J Urol. 1999 May;161(5):1620-5. J Urol. 1999. PMID: 10210429
-
Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.Anticancer Res. 2004 Jul-Aug;24(4):2135-40. Anticancer Res. 2004. PMID: 15330153
-
Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.J Nutr Biochem. 2007 Jun;18(6):408-17. doi: 10.1016/j.jnutbio.2006.08.006. Epub 2006 Dec 4. J Nutr Biochem. 2007. PMID: 17142033
-
The role of angiogenesis in prostate development and the pathogenesis of prostate cancer.Urol Res. 2003 Feb;30(6):347-55. doi: 10.1007/s00240-002-0287-9. Epub 2002 Nov 21. Urol Res. 2003. PMID: 12599013 Review.
-
Some experimental results with prolactin: an overview of effects on the prostate.Prog Clin Biol Res. 1981;75B:55-62. Prog Clin Biol Res. 1981. PMID: 6119702 Review. No abstract available.
Cited by
-
Vascular endothelial growth factor and angiopoietin are required for prostate regeneration.Prostate. 2007 Apr 1;67(5):485-99. doi: 10.1002/pros.20534. Prostate. 2007. PMID: 17221843 Free PMC article.
-
Suppression of DHT-induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells.Prostate. 2013 Jul;73(10):1069-81. doi: 10.1002/pros.22654. Epub 2013 Feb 19. Prostate. 2013. PMID: 23423946 Free PMC article.
-
Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.Endocr Relat Cancer. 2008 Dec;15(4):841-9. doi: 10.1677/ERC-08-0084. Epub 2008 Jul 30. Endocr Relat Cancer. 2008. PMID: 18667687 Free PMC article. Review.
-
Management of an Extensive Intraparotid and Auricular Arteriovenous Malformation.Am J Case Rep. 2022 Apr 4;23:e935337. doi: 10.12659/AJCR.935337. Am J Case Rep. 2022. PMID: 35370285 Free PMC article. Review.
-
Endothelial cells support the growth of prostate tissue in vivo.Prostate. 2008 Jun 1;68(8):893-901. doi: 10.1002/pros.20762. Prostate. 2008. PMID: 18361413 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources